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Clearance of the hepatitis B virus (HBV), a noncyto-
pathic double-stranded DNA virus, requires the coordi-
nated response of innate and adaptive, humoral and cellular
immune systems. In more than 90% of immunocompetent
adults who become infected, this immune response is quite
vigorous, resulting in acute, self-limited hepatitis with rapid
reduction of viral load and long-lasting, protective humoral
and cellular immunity. However, in 5% of HBV-infected
immunocompetent adults, and most cases of vertical trans-
mission of HBV, persistent infection and chronic necroin-
flammatory liver disease evolve which may eventually lead
to liver cirrhosis and hepatocellular carcinoma.
In HBV infection, the cellular immune response is
thought to contribute to both viral clearance and liver cell
injury. These two opposing functions have even been at-
tributed to the same cell: upon cognate recognition of viral
peptides on MHC class I molecules of HBV-infected cells,
 
CD8
 
1
 
 T cells acquire the capacity to either cure HBV-
infected cells via noncytopathic, cytokine-mediated inhibi-
tion of HBV replication or to destroy them via perforin-,
 
Fas ligand (FasL)-, and TNF-
 
a
 
–mediated death pathways.
Both effector functions have been observed during resolu-
tion of acute hepatitis B (1).
Individuals with acute, self-limited HBV infection char-
acteristically mount a vigorous, polyclonal, and multispe-
cific Th and CTL response to epitopes within the HBV en-
velope (HBe), nucleocapsid, and polymerase proteins that
is readily detectable in the peripheral blood. This response
coincides with the maximum elevation of serum alanine
aminotransferase (ALT) levels (2) and precedes clearance of
HBe and surface (HBs) antigens and development of neu-
tralizing antibodies (3). In contrast, the HBV-specific im-
mune response is weak or undetectable in the blood of
chronically infected patients, although individual, HBV-
specific T cell clones have been isolated and expanded from
liver biopsies (4, 5). Since HBV is considered a noncyto-
pathic virus and the degree of the intrahepatic inflamma-
tory leukocytic infiltrate is regarded as the histologic hall-
mark of the severity of chronic hepatitis B, it has been
postulated that the HBV-specific immune response is too
weak to eliminate HBV from all infected hepatocytes, but
sufficiently strong to continuously destroy HBV-infected
hepatocytes and to induce chronic inflammatory liver in
persistently infected individuals. The reason for this ineffi-
cient, yet harmful nature of the cellular immune response
in chronic hepatitis B is currently not known. Is the abso-
lute number of intrahepatic and circulating HBV-specific T
cells too low to clear HBV early in the infection? Are
HBV-specific T cells anergized by high viral load? Do in-
trahepatic HBV-specific T cells exert different effector
functions in chronically infected patients than in those who
control HBV replication? Do intrahepatic T cells recognize
different, e.g., subdominant, HBV epitopes in chronically
infected patients? Or are functional HBV-specific T cells
antagonized by emerging HBV mutants?
 
Finding answers to these questions has been hampered by
 
the fact that HBV does not grow in tissue culture and that the
chimpanzee is the only animal that can be infected with the
virus. HBV-specific T cells have been isolated from liver bi-
opsies of chronically infected patients, but phenotypic and
functional characterization generally required extensive in
vitro expansion (4, 5). This technique unavoidably intro-
duced a selection bias for T cells that could be expanded in
tissue culture, and thus, allowed neither correct quantitation
of HBV-specific T cells within the intrahepatic infiltrate nor
direct ex vivo assessment of T cell function.
 
HBV-specific CTLs and Control of HBV Replication
 
In this issue, Maini et al. (6) use three HBV peptide HLA-
A2 tetramers to compare the number and function of circu-
lating and intrahepatic HBV-specific T cells in two well-
 
defined groups of persistently infected, HBsAg
 
1
 
 patients
with chronic hepatitis B: a group of HBeAg
 
2
 
 patients with
 
low levels of viremia (
 
,
 
2 pg/ml serum), normal serum ALT
levels, and no histologic evidence of intrahepatic inflamma-
 
tion, and a second group of HBeAg
 
1
 
 patients with high
levels of viremia (
 
.
 
800 pg/ml serum), elevated serum ALT
levels, and histologic evidence of chronic hepatitis (6).
Using direct, ex vivo analysis of intrahepatic T cells with
HBV epitope–specific HLA-A2 tetramers, a technique that
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does not require in vitro T cell expansion, Maini et al. (6)
identified CD8
 
1
 
 T cells, specific for the same HBV
epitopes that were recognized by patients with self-limited
hepatitis B (2), in the blood and livers of chronically in-
fected patients who were able to control both viral load
and liver injury. In the liver, CD8
 
1
 
 T cells that recognized
an HBV nucleocapsid epitope constituted up to 9% of all
intrahepatic CD8
 
1
 
 T cells and expressed the activation
marker DR
 
1
 
 (6). In the blood, these cells displayed the
phenotype of antigen-experienced resting cells and were
able to mount rapid IFN-
 
g
 
, cytotoxic, and proliferative re-
sponses. Since none of the patients displayed neutralizing
antibodies against HBsAg, the authors suggest that these in-
trahepatic HBV-specific CD8
 
1
 
 T cells contributed to con-
trol of HBV replication and, importantly, that they were
able to do so without inducing hepatic immunopathology.
Thus, the results that Maini et al. obtained in persistently
infected, HBeAg
 
2
 
 patients with low viral load (6), and ad-
ditional studies by other investigators (7, 8) are leading to a
new appreciation of the function of HBV-specific CD8
 
1
 
 T
cells favoring a protective rather than a pathogenic role in
HBV infection. In addition, several new and puzzling
questions arise with regard to the intrahepatic infiltrate in
HBeAg
 
1
 
 patients with high viral load and elevated liver
enzymes. These will be discussed below.
The report by Maini et al. (6) suggests that chronic hep-
atitis B is not characterized by complete absence of HBV-
specific T cells—instead, there appears to be a balance
between HBV-specific T cells and small amounts of repli-
cating virus that can be maintained without induction of liver
injury. Notably, similar findings have also been reported in
patients who were studied decades after
 
 
 
clinical recovery
from acute and chronic HBV, even after serological clear-
ance of all viral antigens, long-lasting neutralizing antibody
responses, and immunity to reinfection (9–11). The
strength of the HBV-specific CTL response after clinical
recovery correlated with persistence of very small amounts
of HBV DNA in the serum and PBMCs (10). Since the
CTL response was specific for HBV nonstructural proteins
that required synthesis by infected cells, these observations
imply continuous priming of new CTLs by minute traces
of transcriptionally active virus. HBV-specific antibodies
and T cells, in turn, may prevent viral spread and reinfec-
tion and therefore control the remaining virus. Indeed,
HBV reactivation or transmission has been reported if im-
munological control became impaired, e.g., during immu-
nosuppression (12) and after transplantation of organs from
recovered (anti-HBs
 
1
 
, anti-HBcIgM
 
2
 
) donors into immu-
nosuppressed recipients (13). Conceivably, therefore, virus-
specific T cells may persist not only in the peripheral blood,
but also in the liver, as recently reported for intrahepatic
hepatitis C virus (HCV)-specific CD8
 
1
 
 T cells after recov-
ery from acute, self-limited HCV infection (14).
How is this control mediated and why is it not effective
in patients with high viral load? This is one of the key
questions that arise from this study (6). Unfortunately, the
number of tetramer
 
1 
 
cells that were isolated from a given
liver biopsy was too small to compare the function of
 
HBV-specific, intrahepatic T cells in persistently infected
patients who did or did not control viral load (6). Al-
though Maini et al. (6) did not exclude cytotoxic effector
functions of HBV-specific intrahepatic CD8
 
1
 
 T cells, the
sparse scattering of these T cells within liver lobules among
a large number of hepatocytes suggests a more efficient
mechanism that does not require “one to one” contact be-
tween effector and target cell. Specifically, IFN-
 
a
 
/
 
b
 
, IFN-
 
g
 
,
and TNF-
 
a
 
 have been shown to downregulate HBV repli-
cation and gene expression noncytopathically in infected
cells (8). HBV nucleocapsid particles, replicative viral in-
termediates, and the transcriptional template of the virus,
the episomal covalently closed circular (ccc) HBV DNA,
are all susceptible to these cytokine-mediated effects (7).
This mechanism plays an important role in the early phase
of acute HBV infection because downregulation of HBV
replication precedes massive infiltration of CD8
 
1
 
 T cells
and manifestation of liver disease (7). Even a small number
of HBV-specific, intrahepatic T cells may lead to suffi-
ciently high intrahepatic cytokine concentrations to inhibit
HBV replication. McClary et al. reported in a recent study
that constitutive expression of IFN-
 
g
 
 contributed to a
threefold downregulation of HBV replication in the liver
of HBV transgenic mice compared with IFN-
 
g
 
 receptor
and IFN-
 
a
 
/
 
b
 
 receptor knockout mice (15). Moreover,
IFN-
 
g
 
, produced by HBsAg-specific, adoptively trans-
ferred CTLs, was sufficient to inhibit HBV replication in
the livers of HBV transgenic mice that were either unable
to respond to TNF-
 
a
 
 or IFN-
 
a
 
/
 
b
 
 (TNF-
 
a
 
 receptor or
IFN-
 
a
 
/
 
b
 
 receptor knockout mice) or unable to produce
IFN-
 
g
 
 (IFN-
 
g
 
 knockout mice), respectively (15). Thus, it
is possible that curative, IFN-
 
g
 
–mediated, rather than im-
munopathogenic, cytolytic effects of HBV-specific T cells
prevail, if the intrahepatic infiltrate is small and HBV-spe-
cific CD8
 
1
 
 T cells constitute most of it. In addition, IFN-
 
g
 
secretion by intrahepatic CTLs may contribute to optimal
in vivo processing of HBV antigens (16), since it was re-
cently shown that an immunodominant HBV core CTL
epitope was only generated by IFN-
 
g
 
–induced immuno-
proteasomes, not by constitutive proteasomes (17).
Importantly, however, the same mechanisms that con-
tribute to viral clearance in acute hepatitis B may also pre-
vent complete recovery of chronically infected patients.
Partial downregulation of HBV replication and antigen ex-
pression without complete viral clearance may allow in-
fected cells to escape from immune recognition and may
result in low level viral persistence in the absence of liver
injury. This scenario may indeed reflect the apparent bal-
ance between low viral load, absence of liver injury, and
resting, antigen-experienced T cells in the peripheral
blood of persistently infected patients that Maini et al. de-
scribed (6).
 
Function of HBV-specific T Cells—Influenced by Viral Load?
 
How does the intrahepatic cellular infiltrate of persis-
tently infected patients with low viral load differ from that
of patients with high viral load? As expected and typical for
a severe, chronic active form of hepatitis, patients with high 
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viral load displayed a more extensive intrahepatic inflam-
matory infiltrate, extending from the portal areas into the
liver parenchyma (6). Surprisingly, however, Maini et al.
(6) now demonstrate that the absolute number of HBV-
specific intrahepatic T cells that bind to the HB core
(HBc)18–27 peptide HLA tetramer did not differ between
patients with high and those with low viral load. Instead,
HBc18–27-specific T cells were more diluted among liver
infiltrates in highly viremic patients, indicating that the re-
cruitment of these other cells may have contributed to liver
injury. While quantitative differences of T cell populations
that are specific for other HBV epitopes cannot be fully ex-
cluded, Maini et al. (6) raise the important question of
whether the quality rather than the quantity of HBc18–27
specific T cell response differed between both patient
groups.
Because of the limited number of lymphocytes that can
be isolated from a liver biopsy, functional aspects of the
HBV-specific immune response were assessed using HBV-
specific T cells derived from the peripheral blood (6). This
provided valuable and interesting, but not complete, infor-
mation because circulating and intrahepatic HBV-specific
T cells displayed different phenotypes with regard to their
activation status, and thus may have differed in their effec-
tor functions such as cytotoxicity and IFN-
 
g
 
 production as
well (6). HBV-specific CD8
 
1
 
 T cells, isolated from the
blood of patients with low viral load and normal ALT val-
ues, displayed a resting phenotype, but mounted rapid and
vigorous proliferative, IFN-
 
g
 
, and cytotoxic responses
upon reexposure to antigen in vitro.
 
 
 
In contrast, the num-
ber of circulating HBV-specific T cells derived from the
blood of patients with high viral load and elevated serum
ALT levels was lower, and these cells displayed a poor ex-
pansion potential in vitro. Avoiding the bias introduced by
prolonged cell culture, these results now confirm earlier
analyses that depended on in vitro expansion of cells (11,
18). Since it has recently been suggested that individual ef-
fector functions may exhibit different sensitivity to stimula-
tion as well as to functional impairment (19), it will be im-
portant to study additional effector functions of circulating
and intrahepatic HBV-specific T cells in patients with high
viral load with direct ex vivo techniques.
Impaired functions of virus-specific CD8
 
1
 
 T cells have
also been reported in persistent infections with the lym-
phocytic choriomeningitis virus (LCMV) (20) and the neu-
rotropic JHM strain of mouse hepatitis virus (JHMV),
respectively (21). In acute viral infections, functional im-
pairment of virus-specific CD8
 
1
 
 T cells has been observed
when viral load of HBV (2) or LCMV (22) were high. In-
terestingly, impaired functional T cell responsiveness may
be reversible, and the proliferative and cytotoxic function
of HBV-specific T cells recovered after the acute phase of
HBV when their frequency decreased and HBeAg was
cleared (2). Similarly, a small percentage of chronically in-
fected patients experience a spontaneous decrease of HBV
DNA levels and clearance of HBeAg every year, a process
that may be followed by clearance of HBsAg, development
of neutralizing anti-HBs antibodies, and complete recovery
(23). A previously published prospective study supports the
hypothesis that activation of HBV-specific T cell responses
in the peripheral blood precedes spontaneous clearance of
HBeAg in chronically infected patients (24) and suggests
that latent, immune-mediated clearance mechanisms can
become spontaneously activated in some individuals and
may eventually contribute to clearance of HBsAg and com-
plete recovery. Since Maini et al. (6) did not have the op-
portunity to prospectively study these patients, we cannot
be sure that circulating HBV-specific CD8
 
1
 
 T cell re-
sponses increased before the decrease in viral load and
clearance of HBeAg, or whether they appeared afterwards.
This raises the possibility that the CTL response may have
been secondary to the reduction in viral load rather than
causing it. A recent publication supports this hypothesis
(25). Treatment of HBV-infected patients with the antivi-
ral agent lamivudine induced a reduction of viral load that
was followed by recovery of functional, HBV-specific
CD4
 
1
 
 T cell responses in the peripheral blood (25). Thus,
the current study (6) also raises a cautionary note suggesting
that therapeutic enhancement of HBV-specific T cell re-
sponses may not be sufficient to induce viral clearance and
resolution of liver disease and instead, should be accompa-
nied or preceded by attempts to reduce viral load.
 
Immunopathogenesis of HBV
 
Since the absolute number of tetramer
 
1
 
, HBc18–27-spe-
cific T cells did not differ between patients with and with-
out liver injury (6), Maini et al. suggest that the remaining
intrahepatic T cells that were not stained with this tetramer
might be responsible for liver injury. Importantly, these
unstained T cells were more frequently found in the liver
of patients with elevated ALT levels than in those with
normal ALT levels. Since this non-HBc18–27-specific cel-
lular infiltrate may either consist of HBV-specific T cells
that recognize different HBV epitopes or of HBV-nonspe-
cific bystander cells, several questions arise that are not an-
swered in this study (6): Is liver injury predominantly due
to bystander effects of antigen-nonspecific cells? Is it due to
direct interaction between liver-infiltrating cells and hepa-
tocytes, or is it the consequence of the high turnover of
liver-infiltrating CD8
 
1
 
 T cells that presumably do not leave
the liver alive (26)?
During acute, self-limited HBV, maximum ALT levels
coincide with intrahepatic infiltration of CD8
 
1
 
 T cells,
suggesting that these cells mediate acute necroinflammatory
liver disease (7). Proof of this hypothesis was derived from a
series of experiments performed with transgenic mice that
expressed either HBsAg or all HBV proteins in their hepa-
tocytes and replicated the virus. Intravenous injection of
HBsAg-specific CTLs induced an acute, self-limited necro-
inflammatory liver disease (27), and antigen recognition by
the transferred CTLs was identified as the earliest detect-
able pathological event, followed by apoptosis of individual
hepatocytes. Both FasL and perforin pathways had to be ac-
tivated simultaneously by the same CTLs in order to kill
the hepatocyte (28). Importantly, however, most of the
liver injury was not mediated by HBV-specific CTLs, but 
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by antigen-nonspecific inflammatory cells that were re-
cruited into the liver 4–12 h later (29). These cells sur-
rounded HBV-specific CTLs and formed necroinflamma-
tory foci with hepatocellular necrosis (29). Because of the
limited life span of the transferred CTLs that initiated this
cascade, the induced hepatitis was generally transient and
nonfatal in these mice. If the intrahepatic inflammatory in-
filtrate initiated by HBV-specific T cells persisted, as ob-
served in transgenic mouse models of chronic hepatitis B,
chronic necroinflammatory liver disease (30, 31) and ulti-
mately hepatocellular carcinoma (30) was induced.
 
Recruitment and Fate of Intrahepatic T Cells
 
Why do HBV-nonspecific cells migrate into the liver?
And, provided that the majority of tetramer
 
2
 
 cells were in-
deed HBV nonspecific in the study by Maini et al. (6), why
were they predominantly attracted into the livers of persis-
tently infected, HBeAg
 
1
 
 patients with high viral load, and
less frequently into those of persistently infected, HBeAg
 
2
 
patients with low viral load? These questions lead again to
the critical point of the study, to the function of HBV-spe-
cific intrahepatic T cells. If the absolute number of HBV-
specific intrahepatic T cells was comparable in both patient
groups, is it possible that functional differences extend not
only to their antiviral effects as suggested by Maini et al.
(6), but also to their ability to recruit antigen-nonspecific T
cells? Or are the size and composition of the intrahepatic
inflammatory infiltrate influenced by viral load and intrahe-
patic expression and secretion of HBeAg?
In addition, the kinetics of T cell recruitment into the
liver and T cell turnover in the liver have to be considered.
Low blood flow and branched structure of the intrahepatic
vascular bed and mobility of the Kupffer cells facilitate re-
cruitment of T cells from the peripheral blood (32) by ex-
pression of chemokines and adhesion molecules (26). Since
certain adhesion molecules are constitutively expressed in
the noninflamed liver and upregulated during infection, ac-
tivated CD8
 
1
 
 T cells are continuously trapped in the liver
regardless of the antigen specificity (26). Accordingly, a
high percentage of influenza-specific T cells has been de-
tected in the liver of influenza virus–infected mice (33).
What is the fate of these T cells? Mehal et al. recently de-
scribed that activated, CD8
 
1
 
 but not CD4
 
1
 
 T cells un-
dergo apoptosis within 18 h of entry into the liver (26). In-
deed, the liver has been described as a graveyard for
activated T cells (33) and is thought to contribute to ho-
meostasis of the T cell repertoire after pathogen-induced
expansion of antigen-specific T cell clones.
Thus, even an equal number of HBV-specific T cells
that Maini et al. (6) describe in liver biopsies of HBV-
infected patients with high and low viral load may still be
compatible with different rates of T cell recruitment and
turnover. After antigen recognition and exertion of their
specific effector function, virus-specific effector CTLs are
prone to undergo activation-induced cell death. This cas-
cade of events may occur rapidly in the presence of high
concentrations of HBV antigens and the absence of suffi-
cient costimulation. Notably, with regard to chronic HCV
 
infection, Nuti et al. estimated a loss of 2 
 
3
 
 10
 
8
 
 T cells in
the liver, which equals 0.1% of the total body lymphocytes,
per day (32). Thus, an accelerated T cell turnover in the
liver would be compatible with the lower frequencies of
circulating antigen-specific T cells that Maini et al. (6) de-
scribed in patients with high viral load. If, on the contrary,
the concentration of intrahepatic viral antigens and the de-
gree of inflammation are low, HBV-specific T cells may
enter the liver less frequently and succumb to a slower
death due to cytokine starvation. While this notion is
strictly speculative at present, analysis of the kinetics of T
cell induction and turnover may represent an important
area of research, especially if the liver is the primary organ
of viral replication.
 
Further Questions
 
The study and findings reported by Maini et al. (6) will
certainly stimulate efforts to study both quantitative and
qualitative aspects of the intrahepatic, HBV-specific cellular
immune responses with techniques that allow direct, ex
vivo analysis of antigen-specific T cells. In addition, they
may draw attention to the composition, effector function,
migration pattern, and fate of the intrahepatic cellular infil-
trate in chronic HBV. Several interesting questions are
raised and remain to be addressed.
The first set of questions addresses the functional state of
intrahepatic, HBV-specific T cells in chronically infected
patients with high viral load and evidence of liver injury.
Why are these intrahepatic HBV-specific T cells not able
to exert sufficient antiviral control? Note that they are
found in the same quantity as in the liver of patients who
control viral load. Are they inhibited or are their effects
outnumbered by supposedly HBV-nonspecific T cells? Do
HBV-nonspecific bystander cells shift the cytokine balance
in an unfavorable way? Or are HBV-specific T cells aner-
gized, as recently reported in a prospective study of patients
with chronically evolving, acute HBV (34)? If the number
of intrahepatic T cells is the same in both patient groups, it
should be possible, although technically difficult, to com-
pare their phenotype and function with direct, ex vivo
techniques.
Related questions address the phenotype, specificity, and
function of the intrahepatic cellular infiltrate that did not
react with the HBV tetramers used in this study: Are these
lymphocytes HBV-nonspecific bystander cells or are they
targeted against other, potentially subdominant HBV
epitopes? If they are HBV-nonspecific bystander cells, why
do they become activated during HBV infection? Do they
express specific chemokine receptor, such as CC chemo-
kine receptor 5 (CCR5), that attracts them to the liver?
What is the fate and life span of HBV-specific and -non-
specific T cells once they reach the liver? Can migration
and/or function of these liver-infiltrating HBV-nonspecific
T cells be inhibited?
Finally, the last group of questions addresses the function
and role of specialized antigen-presenting cells that are
characteristic for the liver. Both Kupffer cells and sinusoidal
endothelial cells have been shown to internalize and 
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present soluble antigen and thus, may exert immune regu-
latory functions. Do they exert stimulatory (35) or tolero-
genic (36) effects on intrahepatic lymphocytes? Do they
initiate recruitment of antigen-nonspecific cells? Which
stimuli are required to induce production of antiviral cy-
tokines in intrahepatic macrophages, which are considered
potent producers of TNF-
 
a
 
 and IFN-
 
a
 
/
 
b
 
 and play an im-
portant role in downregulation of HBV replication? Is their
function impaired in chronic HBV?
Answers to these questions may contribute to our future
understanding of the immunopathogenesis of chronic HBV
and the tight balance between liver injury and viral control.
Since both liver injury and viral control can be mediated by
the immune system of the infected host, more information
is needed before antigen-specific immunotherapy of
chronic HBV infection should be attempted.
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